دورية أكاديمية
أعرض في EDS

The long Pentraxin PTX3 serves as an early predictive biomarker of co-infections in COVID-19.

التفاصيل البيبلوغرافية
العنوان: The long Pentraxin PTX3 serves as an early predictive biomarker of co-infections in COVID-19.
المؤلفون: Scavello F; IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy., Brunetta E; Infectious Diseases Unit, Hospital Health Direction, IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy., Mapelli SN; IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy., Nappi E; IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, 20072, Pieve Emanuele, Milan, Italy., García Martín ID; Department of Biomedical Sciences, Humanitas University, 20072, Pieve Emanuele, Milan, Italy., Sironi M; IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy., Leone R; IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy., Solano S; IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy., Angelotti G; Artificial Intelligence Center, IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy., Supino D; IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy., Carnevale S; IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy., Zhong H; IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, 20072, Pieve Emanuele, Milan, Italy., Magrini E; IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy., Stravalaci M; IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy., Protti A; Department of Biomedical Sciences, Humanitas University, 20072, Pieve Emanuele, Milan, Italy; Department of Anesthesia and Intensive Care, IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy., Santini A; Department of Biomedical Sciences, Humanitas University, 20072, Pieve Emanuele, Milan, Italy; Department of Anesthesia and Intensive Care, IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy., Costantini E; Department of Anesthesia and Intensive Care, IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy., Savevski V; Artificial Intelligence Center, IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy., Voza A; Department of Biomedical Sciences, Humanitas University, 20072, Pieve Emanuele, Milan, Italy; Emergency Department, IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy., Bottazzi B; IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy., Bartoletti M; Infectious Diseases Unit, Hospital Health Direction, IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, 20072, Pieve Emanuele, Milan, Italy., Cecconi M; Department of Biomedical Sciences, Humanitas University, 20072, Pieve Emanuele, Milan, Italy; Department of Anesthesia and Intensive Care, IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy., Mantovani A; IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, 20072, Pieve Emanuele, Milan, Italy; The William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK., Morelli P; Infectious Diseases Unit, Hospital Health Direction, IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy., Tordato F; Infectious Diseases Unit, Hospital Health Direction, IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy., Garlanda C; IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, 20072, Pieve Emanuele, Milan, Italy. Electronic address: cecilia.garlanda@humanitasresearch.it.
المصدر: EBioMedicine [EBioMedicine] 2024 Jul; Vol. 105, pp. 105213. Date of Electronic Publication: 2024 Jun 21.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3964 (Electronic) Linking ISSN: 23523964 NLM ISO Abbreviation: EBioMedicine Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam] : Elsevier B.V., [2014]-
مواضيع طبية MeSH: COVID-19*/blood , COVID-19*/diagnosis , C-Reactive Protein*/metabolism , C-Reactive Protein*/analysis , Serum Amyloid P-Component*/metabolism , Biomarkers*/blood , Coinfection* , SARS-CoV-2*/isolation & purification, Humans ; Male ; Female ; Aged ; Middle Aged ; Bacterial Infections/blood ; Bacterial Infections/diagnosis ; Procalcitonin/blood ; Prognosis ; Mycoses/blood ; Mycoses/diagnosis ; Aged, 80 and over
مستخلص: Background: COVID-19 clinical course is highly variable and secondary infections contribute to COVID-19 complexity. Early detection of secondary infections is clinically relevant for patient outcome. Procalcitonin (PCT) and C-reactive protein (CRP) are the most used biomarkers of infections. Pentraxin 3 (PTX3) is an acute phase protein with promising performance as early biomarker in infections. In patients with COVID-19, PTX3 plasma concentrations at hospital admission are independent predictor of poor outcome. In this study, we assessed whether PTX3 contributes to early identification of co-infections during the course of COVID-19.
Methods: We analyzed PTX3 levels in patients affected by COVID-19 with (n = 101) or without (n = 179) community or hospital-acquired fungal or bacterial secondary infections (CAIs or HAIs).
Findings: PTX3 plasma concentrations at diagnosis of CAI or HAI were significantly higher than those in patients without secondary infections. Compared to PCT and CRP, the increase of PTX3 plasma levels was associated with the highest hazard ratio for CAIs and HAIs (aHR 11.68 and 24.90). In multivariable Cox regression analysis, PTX3 was also the most significant predictor of 28-days mortality or intensive care unit admission of patients with potential co-infections, faring more pronounced than CRP and PCT.
Interpretation: PTX3 is a promising predictive biomarker for early identification and risk stratification of patients with COVID-19 and co-infections.
Funding: Dolce & Gabbana fashion house donation; Ministero della Salute for COVID-19; EU funding within the MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (Project no. PE00000007, INF-ACT) and MUR PNRR Italian network of excellence for advanced diagnosis (Project no. PNC-E3-2022-23683266 PNC-HLS-DA); EU MSCA (project CORVOS 860044).
Competing Interests: Declaration of interests A.M., B.B. and C.G. are inventors of a patent (EP20182181) on PTX3 and obtain royalties on related reagents. The other authors declare no competing interests.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
References: Crit Care Med. 2001 Jul;29(7):1404-7. (PMID: 11445697)
Physiol Rev. 2018 Apr 1;98(2):623-639. (PMID: 29412047)
J Infect. 2022 Oct;85(4):374-381. (PMID: 35781017)
Clin Chim Acta. 2020 Jun;505:190-191. (PMID: 32145275)
Antibiotics (Basel). 2021 Nov 22;10(11):. (PMID: 34827363)
Immunity. 2014 Apr 17;40(4):621-32. (PMID: 24745336)
J Innate Immun. 2022;14(5):493-501. (PMID: 35066500)
Infect Dis Rep. 2022 May 12;14(3):372-382. (PMID: 35645220)
JAMA. 2020 Mar 17;323(11):1061-1069. (PMID: 32031570)
JAMA Cardiol. 2020 Jul 1;5(7):811-818. (PMID: 32219356)
Cell. 2021 Apr 1;184(7):1671-1692. (PMID: 33743212)
Front Immunol. 2019 May 29;10:1135. (PMID: 31191526)
Thorax. 2020 Nov;75(11):974-981. (PMID: 32826284)
Lancet. 2022 Feb 12;399(10325):629-655. (PMID: 35065702)
PLoS One. 2013;8(1):e53661. (PMID: 23341967)
Leukemia. 2021 Sep;35(9):2710-2714. (PMID: 34031531)
JAC Antimicrob Resist. 2021 Nov 28;3(4):dlab180. (PMID: 34859223)
Crit Care. 2014 Oct 15;18(5):562. (PMID: 25314919)
Nat Immunol. 2021 Jan;22(1):19-24. (PMID: 33208929)
Crit Care. 2020 Oct 6;24(1):600. (PMID: 33023606)
Nat Commun. 2021 Jun 7;12(1):3406. (PMID: 34099652)
Front Immunol. 2019 Apr 17;10:823. (PMID: 31057548)
Crit Care. 2021 Aug 5;25(1):281. (PMID: 34353339)
J Infect. 2021 Apr;82(4):84-123. (PMID: 33147434)
Eur Heart J. 2021 Jun 14;42(23):2270-2279. (PMID: 33448289)
J Infect. 2020 Aug;81(2):266-275. (PMID: 32473235)
Stat Med. 1996 Feb 28;15(4):361-87. (PMID: 8668867)
J Biol Chem. 2008 Oct 31;283(44):29983-92. (PMID: 18703503)
J Clin Virol. 2020 Jun;127:104370. (PMID: 32344321)
Int J Antimicrob Agents. 2020 Aug;56(2):106051. (PMID: 32534186)
J Microbiol Immunol Infect. 2022 Dec;55(6 Pt 1):985-992. (PMID: 36243668)
Intensive Care Med. 2023 Aug;49(8):934-945. (PMID: 37507573)
Crit Care. 2022 Aug 3;26(1):236. (PMID: 35922860)
Circulation. 2004 Oct 19;110(16):2349-54. (PMID: 15477419)
Biomed Res Int. 2019 Apr 2;2019:2639248. (PMID: 31061822)
Transplantation. 2012 Nov 27;94(10):1060-5. (PMID: 23104251)
J Exp Med. 2007 Apr 16;204(4):793-804. (PMID: 17389238)
AIDS Res Hum Retroviruses. 2024 Feb;40(2):110-113. (PMID: 37335044)
Clin Microbiol Infect. 2020 Dec;26(12):1622-1629. (PMID: 32711058)
Antimicrob Agents Chemother. 2021 Mar 18;65(4):. (PMID: 33495224)
Antibiotics (Basel). 2022 Mar 09;11(3):. (PMID: 35326830)
J Clin Invest. 2003 Jun;111(12):1805-12. (PMID: 12813013)
N Engl J Med. 2023 Feb 2;388(5):439-452. (PMID: 36724330)
Clin Microbiol Infect. 2021 Jan;27(1):9-11. (PMID: 32979569)
Clin Microbiol Infect. 2021 Jan;27(1):83-88. (PMID: 32745596)
Antibiotics (Basel). 2023 Jan 12;12(1):. (PMID: 36671362)
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468. (PMID: 32358954)
Clin Microbiol Infect. 2020 Oct;26(10):1395-1399. (PMID: 32603803)
Front Immunol. 2022 Sep 15;13:979232. (PMID: 36189302)
Nat Immunol. 2022 Feb;23(2):210-216. (PMID: 35027728)
J Infect. 2010 Feb;60(2):122-7. (PMID: 19961874)
Nat Immunol. 2010 Apr;11(4):328-34. (PMID: 20208538)
JAMA Intern Med. 2020 Jul 1;180(7):934-943. (PMID: 32167524)
Allergy. 2020 Jul;75(7):1730-1741. (PMID: 32077115)
Nat Immunol. 2022 Feb;23(2):275-286. (PMID: 35102342)
Front Cell Infect Microbiol. 2022 Feb 23;12:784130. (PMID: 35281440)
JAMA. 2022 Aug 23;328(8):702. (PMID: 35997721)
Eur J Clin Invest. 2017 Jan;47(1):73-83. (PMID: 27864924)
Eur J Clin Invest. 2021 May;51(5):e13530. (PMID: 33660256)
J Infect. 2021 Nov;83(5):607-635. (PMID: 34400218)
J Antimicrob Chemother. 2021 Apr 13;76(5):1323-1331. (PMID: 33463683)
Front Immunol. 2022 Oct 28;13:933960. (PMID: 36389697)
Front Immunol. 2019 Apr 12;10:794. (PMID: 31031772)
Infection. 2021 Oct;49(5):935-943. (PMID: 34021897)
Clin Infect Dis. 2021 Apr 26;72(8):1450-1452. (PMID: 32604413)
فهرسة مساهمة: Keywords: Biomarker; COVID-19; Community-acquired infections; Hospital-acquired infections; PTX3
المشرفين على المادة: 148591-49-5 (PTX3 protein)
9007-41-4 (C-Reactive Protein)
0 (Serum Amyloid P-Component)
0 (Biomarkers)
0 (Procalcitonin)
تواريخ الأحداث: Date Created: 20240622 Date Completed: 20240712 Latest Revision: 20240802
رمز التحديث: 20240802
مُعرف محوري في PubMed: PMC11245991
DOI: 10.1016/j.ebiom.2024.105213
PMID: 38908098
قاعدة البيانات: MEDLINE
الوصف
تدمد:2352-3964
DOI:10.1016/j.ebiom.2024.105213